查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1291233

RNA干扰（RNAi）给药市场：2023-2028年全球行业趋势、份额、规模、增长、机会和预测

RNA Interference (RNAi) Drug Delivery Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3个工作天内

价格

市场概述：

2022年，全球RNA干扰（RNAi）药物输送市场规模达到692亿美元。展望未来，IMARC集团预计，到2028年，市场规模将达到2351亿美元，在2023-2028年期间呈现21.4%的增长率（CAGR）。

核糖核酸干扰（RNAi）给药是指监测基因表达或变异的治疗方案。RNAi给药通常通过静脉注射、皮内注射和腹膜内注射以及局部给药方法进行。它涉及纳米颗粒、肺部、核酸和诱导剂药物输送技术。这些技术也被用于分析真核生物的基因功能和开发治疗性基因沉默方案。因此，RNAi药物输送被广泛用于治疗传染病、慢性代谢紊乱、心血管、神经系统、泌尿系统、肿瘤和眼科疾病。

全球范围内慢性医疗和遗传疾病，如癌症和心血管疾病（CVDs）的发病率越来越高，是推动市场增长的关键因素之一。此外，老年人口的增加，更容易受到这些疾病的影响，也在推动市场的增长。与此相呼应，随着冠状病毒疾病（COVID-19）继续在全球蔓延，对RNAi药物递送技术的需求也大幅增加。靶向给药方法，如适配体给药系统，在抗病毒药物的给药方面正获得巨大的吸引力，因为它们是由小干扰RNA（siRNA）诱导的，可以抑制病毒抗原的表达。此外，各种技术进步，如创新的合成递送载体和生物载体的开发，预计将推动市场增长。纳米载体，包括siRNA或microRNA（miRNA），对于开发个性化药物和识别改变的细胞分子和代谢物至关重要。其他因素，包括纳米技术和分子诊断领域的广泛研究和开发（R&D）活动，以及医疗基础设施的整体改善，预计将进一步推动市场。

本报告回答的关键问题：

  • 迄今为止，全球RNA干扰（RNAi）给药市场的表现如何，在未来几年将如何表现？
  • COVID-19对全球RNA干扰（RNAi）给药市场的影响是什么？
  • 主要的区域市场是什么？
  • 基于应用的市场细分是什么？
  • 基于技术的市场细分是什么？
  • 该行业价值链的各个阶段是什么？
  • 该行业的关键驱动因素和挑战是什么？
  • 全球RNA干扰（RNAi）给药市场的结构是什么，谁是主要参与者？
  • 该行业的竞争程度如何？

目录

第一章：前言

第二章：范围和方法

  • 研究的目标
  • 利益相关者
  • 数据来源
    • 主要来源
    • 二级来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：全球RNA干扰（RNAi）给药市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：按应用领域分類的市场

  • 传染性疾病
    • 市场趋势
    • 市场预测
  • 心脏病学
    • 市场趋势
    • 市场预测
  • 肿瘤学
    • 市场趋势
    • 市场预测
  • 神经病学
    • 市场趋势
    • 市场预测
  • 眼科
    • 市场趋势
    • 市场预测
  • 泌尿外科
    • 市场趋势
    • 市场预测
  • 代谢性疾病
    • 市场趋势
    • 市场预测
  • 其他
    • 市场趋势
    • 市场预测

第7章 ：按技术分類的市场

  • 纳米颗粒给药
    • 市场趋势
    • 市场预测
  • 肺部给药
    • 市场趋势
    • 市场预测
  • 核酸给药
    • 市场趋势
    • 市场预测
  • 合剂给药
    • 市场趋势
    • 市场预测

第8章：按地区分類的市场

  • 北美洲
    • 美国
      • 市场趋势
      • 市场预测
    • 加拿大
      • 市场趋势
      • 市场预测
  • 亚太地区
    • 中国
      • 市场趋势
      • 市场预测
    • 日本
      • 市场趋势
      • 市场预测
    • 印度
      • 市场趋势
      • 市场预测
    • 韩国
      • 市场趋势
      • 市场预测
    • 澳大利亚
      • 市场趋势
      • 市场预测
    • 印尼
      • 市场趋势
      • 市场预测
    • 其他国家
      • 市场趋势
      • 市场预测
  • 欧洲
    • 德国
      • 市场趋势
      • 市场预测
    • 法国
      • 市场趋势
      • 市场预测
    • 英国
      • 市场趋势
      • 市场预测
    • 意大利
      • 市场趋势
      • 市场预测
    • 西班牙
      • 市场趋势
      • 市场预测
    • 俄罗斯
      • 市场趋势
      • 市场预测
    • 其他国家
      • 市场趋势
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场趋势
      • 市场预测
    • 墨西哥
      • 市场趋势
      • 市场预测
    • 其他国家
      • 市场趋势
      • 市场预测
  • 中东和非洲
    • 市场趋势
    • 按国家分類的市场
    • 市场预测

第九章：SWOT分析

  • 概述
  • 优势
  • 劣势
  • 机会
  • 威胁

第十章：价值链分析

第十一章 ：波特斯五力分析

  • 概述
  • 买方的讨价还价能力
  • 供应商的讨价还价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第十二章 ：价格分析

第十三章 ：竞争格局

  • 市场结构
  • 主要参与者
  • 主要参与者的概况
    • Alnylam Pharmaceuticals Inc.
    • Arrowhead Pharmaceuticals Inc.
    • CureVac AG
    • Dicerna Pharmaceuticals Inc.
    • Gradalis Inc.
    • Ionis Pharmaceuticals Inc
    • Merck & Co. Inc.
    • Moderna Inc.
    • Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
    • Silence Therapeutics Plc
    • Sirnaomics Inc.
Product Code: SR112023A2758

Market Overview:

The global RNA interference (RNAi) drug delivery market size reached US$ 69.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 235.1 Billion by 2028, exhibiting a growth rate (CAGR) of 21.4% during 2023-2028.

Ribonucleic acid interference (RNAi) drug delivery refers to a therapeutic solution to monitor gene expression or mutations. RNAi drug delivery is usually administered through intravenous, intra-dermal and intraperitoneal injections and topical delivery methods. It involves nanoparticle, pulmonary, nucleic acid and aptamer drug delivery technologies. These technologies are also used for analyzing gene functions in eukaryotes and developing therapeutic gene silencing solutions. As a result, RNAi drug delivery is widely used for treating infectious diseases, chronic metabolic disorders, cardiovascular, neurological, urological, oncological and ophthalmological disorders.

The increasing prevalence of chronic medical and genetic disorders, such as cancer and cardiovascular diseases (CVDs) across the globe, represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, as the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for RNAi drug delivery technologies. Targeted delivery methods, such as aptamer drug delivery systems, are gaining immense traction for the administration of antiviral drugs as they are induced by small interfering RNA (siRNA) that can inhibit the expression of viral antigens. Additionally, various technological advancements, such as the development of innovative synthetic delivery carriers and bio-vectors, are anticipated to drive the market growth. The nanocarriers, including siRNA or microRNAs (miRNA), are crucial for developing personalized medicines and identifying altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in the fields of nanotechnology and molecular diagnostics, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global RNA interference (RNAi) drug delivery market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on application and technology.

Breakup by Application:

  • Infectious Disease
  • Cardiology
  • Oncology
  • Neurology
  • Ophthalmology
  • Urology
  • Metabolic Disorders
  • Others

Breakup by Technology:

  • Nanoparticle Drug Delivery
  • Pulmonary Drug Delivery
  • Nucleic Acid Drug Delivery
  • Aptamer Drug Delivery

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac AG, Dicerna Pharmaceuticals Inc., Gradalis Inc., Ionis Pharmaceuticals Inc, Merck & Co. Inc., Moderna Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Silence Therapeutics Plc and Sirnaomics Inc.

Key Questions Answered in This Report:

  • How has the global RNA interference (RNAi) drug delivery market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global RNA interference (RNAi) drug delivery market?
  • What are the key regional markets?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the technology?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global RNA interference (RNAi) drug delivery market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1   Preface

2   Scope and Methodology 

  • 2.1  Objectives of the Study
  • 2.2  Stakeholders
  • 2.3  Data Sources
    • 2.3.1  Primary Sources
    • 2.3.2  Secondary Sources
  • 2.4  Market Estimation
    • 2.4.1  Bottom-Up Approach
    • 2.4.2  Top-Down Approach
  • 2.5  Forecasting Methodology

3   Executive Summary

4   Introduction

  • 4.1  Overview
  • 4.2  Key Industry Trends

5   Global RNA Interference (RNAi) Drug Delivery Market

  • 5.1  Market Overview
  • 5.2  Market Performance
  • 5.3  Impact of COVID-19
  • 5.4  Market Forecast

6   Market Breakup by Application

  • 6.1  Infectious Disease
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2  Cardiology
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3  Oncology
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4  Neurology
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5  Ophthalmology
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6  Urology
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7  Metabolic Disorders
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8  Others
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7   Market Breakup by Technology

  • 7.1  Nanoparticle Drug Delivery
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2  Pulmonary Drug Delivery
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3  Nucleic Acid Drug Delivery
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4  Aptamer Drug Delivery
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8   Market Breakup by Region

  • 8.1  North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2  Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3  Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4  Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5  Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9   SWOT Analysis

  • 9.1  Overview
  • 9.2  Strengths
  • 9.3  Weaknesses
  • 9.4  Opportunities
  • 9.5  Threats

10  Value Chain Analysis

11  Porters Five Forces Analysis

  • 11.1  Overview
  • 11.2  Bargaining Power of Buyers
  • 11.3  Bargaining Power of Suppliers
  • 11.4  Degree of Competition
  • 11.5  Threat of New Entrants
  • 11.6  Threat of Substitutes

12  Price Analysis

13  Competitive Landscape

  • 13.1  Market Structure
  • 13.2  Key Players
  • 13.3  Profiles of Key Players
    • 13.3.1  Alnylam Pharmaceuticals Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio 
      • 13.3.1.3 Financials 
      • 13.3.1.4 SWOT Analysis
    • 13.3.2  Arrowhead Pharmaceuticals Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials 
    • 13.3.3  CureVac AG
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio 
      • 13.3.3.3 Financials
    • 13.3.4  Dicerna Pharmaceuticals Inc.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio 
      • 13.3.4.3 Financials
    • 13.3.5  Gradalis Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio 
    • 13.3.6  Ionis Pharmaceuticals Inc
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio 
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7  Merck & Co. Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials 
      • 13.3.7.4 SWOT Analysis
    • 13.3.8  Moderna Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio 
      • 13.3.8.3 Financials 
    • 13.3.9  Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
    • 13.3.10  Silence Therapeutics Plc
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio 
      • 13.3.10.3 Financials 
    • 13.3.11  Sirnaomics Inc.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio 

List of Figures

  • Figure 1: Global: RNA Interference (RNAi) Drug Delivery Market: Major Drivers and Challenges
  • Figure 2: Global: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Application (in %), 2022
  • Figure 4: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Technology (in %), 2022
  • Figure 5: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Region (in %), 2022
  • Figure 6: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 7: Global: RNA Interference (RNAi) Drug Delivery (Infectious Disease) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 8: Global: RNA Interference (RNAi) Drug Delivery (Infectious Disease) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 9: Global: RNA Interference (RNAi) Drug Delivery (Cardiology) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: RNA Interference (RNAi) Drug Delivery (Cardiology) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: RNA Interference (RNAi) Drug Delivery (Oncology) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: RNA Interference (RNAi) Drug Delivery (Oncology) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: RNA Interference (RNAi) Drug Delivery (Neurology) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: RNA Interference (RNAi) Drug Delivery (Neurology) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: RNA Interference (RNAi) Drug Delivery (Ophthalmology) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: RNA Interference (RNAi) Drug Delivery (Ophthalmology) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: RNA Interference (RNAi) Drug Delivery (Urology) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: RNA Interference (RNAi) Drug Delivery (Urology) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: RNA Interference (RNAi) Drug Delivery (Metabolic Disorders) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: RNA Interference (RNAi) Drug Delivery (Metabolic Disorders) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: RNA Interference (RNAi) Drug Delivery (Other Applications) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: RNA Interference (RNAi) Drug Delivery (Other Applications) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: RNA Interference (RNAi) Drug Delivery (Nanoparticle Drug Delivery) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: RNA Interference (RNAi) Drug Delivery (Nanoparticle Drug Delivery) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: RNA Interference (RNAi) Drug Delivery (Pulmonary Drug Delivery) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: RNA Interference (RNAi) Drug Delivery (Pulmonary Drug Delivery) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Global: RNA Interference (RNAi) Drug Delivery (Nucleic Acid Drug Delivery) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Global: RNA Interference (RNAi) Drug Delivery (Nucleic Acid Drug Delivery) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Global: RNA Interference (RNAi) Drug Delivery (Aptamer Drug Delivery) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Global: RNA Interference (RNAi) Drug Delivery (Aptamer Drug Delivery) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: North America: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: North America: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: United States: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: United States: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Canada: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Canada: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: Asia Pacific: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: Asia Pacific: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: China: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: China: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: Japan: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: Japan: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: India: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: India: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: South Korea: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: South Korea: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: Australia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: Australia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Indonesia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Indonesia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: Europe: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: Europe: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: Germany: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: Germany: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: France: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: France: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: United Kingdom: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: United Kingdom: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: Italy: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: Italy: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Spain: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Spain: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Russia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Russia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Latin America: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Latin America: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Brazil: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Brazil: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Mexico: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: Mexico: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 76: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Middle East and Africa: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 78: Middle East and Africa: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 79: Global: RNA Interference (RNAi) Drug Delivery Industry: SWOT Analysis
  • Figure 80: Global: RNA Interference (RNAi) Drug Delivery Industry: Value Chain Analysis
  • Figure 81: Global: RNA Interference (RNAi) Drug Delivery Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: RNA Interference (RNAi) Drug Delivery Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Application (in Million US$), 2023-2028
  • Table 3: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Technology (in Million US$), 2023-2028
  • Table 4: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 5: Global: RNA Interference (RNAi) Drug Delivery Market Structure
  • Table 6: Global: RNA Interference (RNAi) Drug Delivery Market: Key Players